中国药理学通报2017，Vol.33Issue(7)：997-1002,6.DOI:10.3969/j.issn.1001-1978.2017.07.022
针对HER-2的多肽疫苗CKL9与YL20的抗肿瘤活性研究
Anti-tumor activity of HER-specific peptide vaccines-CKL9 and YL20
摘要
Abstract
Aim To explore whether the polypeptide vaccines CKL9 and YL20 can induce immune response and anti-tumor effect on HER-2 (+) tumors in vitro and in vivo, and to provide suggestions for clinical use.Methods The proliferation of specific lymphocytes and cytotoxic T lymphocyte activity(CTL) stimulated by CKL9 and YL20 were studied with CCK-8 assay and LDH assay, and the antitumor activity of CKL9 and YL20 was evaluated in vivo.Results The lymphocyte proliferation was promoted by incubation with CKL9 and YL20, and the relative increase of cells was 11.1% and 16.7% respectively at the concentration of 50 mg·L-1 of CKL9 and YL20.The LDH assay confirmed the CTL effect induced by CKL9 and YL20 on HER2-positive tumor cells, not on HER2-negtive tumor cells.With an effector-target ratio of 80 ∶1, the inhibition of tumor cell by cytotoxic T lymphocyte stimulated by CKL9 and YL20 could reach 89.8% and 84.3%, respectively.The HER2(+) tumor cell N87 transplanted in Babes mice was inhibited by pre-immune polypeptide CKL9 and YL20.Conclusion The HER2-specific polypeptide vaccines CKL9 and YL20 could induce persistent specific CD4 and CD8 T cell immune and inhibit the growth of HER2 positive tumor cells.关键词
HER-2/多肽疫苗/T淋巴细胞/免疫应答/N87移植瘤/抗肿瘤活性Key words
HER-2/neu/peptide vaccination/T-lymphocyte/immune response/N87/anti-tumor分类
医药卫生引用本文复制引用
陈龙冠,宋燕,许元生,黄云娜,覃锦红,谢秋玲..针对HER-2的多肽疫苗CKL9与YL20的抗肿瘤活性研究[J].中国药理学通报,2017,33(7):997-1002,6.基金项目
广东省科技计划项目(No 2015A020211016) （No 2015A020211016）
